Boehringer Mannheim Gmbh

Roche Diagnostics Gmbh

Other

Georgia Tech Research Corporation

Dako A/s

Pna Diagnostics A/s

Boehringer Mannhiem Gmbh

Tschechoslowakische Academie Der Wissenschaften

Hans-Georg Batz

Gunter Weimann

Christian Klein

Rupert Herrmann

Klaus Stellner

Hans-Ralf Linke

Herbert Von Der Eltz

Helmut Lenz

Henrik Frydenlund Hansen

Troels Koch

Winfried Albert

Jurgen Horn

Wolfgang Gruber

Joachim Siedel

Ulrich Neumann

Ulrich Essig

Joachim Ziegenhorn

Josef Maier

Peter Sluka

Henrik Orum

Christa Hubner-Parajsz

Klaus Muhlegger

August W Wahlefeld

Wolfgang Rollinger

Lorenz Kerscher

Michael Nelboeck-Hochstetter

Brigitte Pautz

Martina Junius

Sibylle Berner

Heinz-Hartmut Seliger

Christoph Seidel

Erasmus Huber

Danith H Ly

Frank Seela

Sigmar Klose

Ulfert Deneke

Albert Roder

Eva Hoess

Jaroslav Kalal

Elli Rauscher

Manfred Kuhr

Frantisek Svec

Fritz Stahler

Herbert Jungfer

Alexander Hagen

Helmut Schlumberger

Bernd Vogt

Manfred Baier

Herbert Buschek

Brigitte Draeger

Kurt W Naujoks

Karl Wulff

Dieter Jaworek

Wolfgang Weckerle

Karel Bouchal

Michael Nelbock-Hochstetter

Siegfried Looser

Bruce Alan Armitage

Klaus M&uuml;hlegger

Bruno Zink

Gary B Schuster

Fritz Topfmeier

Eva Zurkova

Paul Tanswell

Wolfgang Kleeman

Rudolf Machat

Gary B Shuster

Herbert Hopp

Gunter Wiemann

Michael Stoltz

Heinz-Peter Muth

Klaus Kaiser

Werner Bourgeois

Emasmus Huber

Bruce A Armitage

Nucleic acid analogs provide a particularly useful tool for the preparation of complex polymeric structures of defined geometry because they are relatively stable to reaction conditions for the preparation of such structures and provide the opportunity to induce reactive groups which would not be possible with usual nucleic acids.

2- or 3-dimensional geometric structures

Nucleic acid analogues provide a particularly useful tool for the preparation of complex polymeric structures of defined geometry because they are relatively stable to reaction conditions for the preparation of such structures and provide the opportunity to introduce reactive groups which would not be possible with usual nucleic acids. These supramolecular structures can be used to form fine networks in nanometer size, for the preparation of e.g., computer chips, new materials/polymers with conductivity and/or insulator properties, and robot arms in nanometer scale.

2-or 3-dimensional geometric structures

New electron transfer moiety labeled nucleic acid analogue probes are provided that can be used in methods for determining nucleic acids in a sample. The new probes can be prepared using novel monomer subunits in a chemical synthesis route. The nucleic acids can be determined by binding the probe molecules to the nucleic acid and inducing electron transfer within the complex formed. The occurrence of the electron transfer is determined as a measure of the nucleic acid.

Method for determining a nucleic acid

The present invention provides desazapurine-nucleoside derivatives of the general formula:

Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents

The invention relates to derivatives of hepatitis C virus amino acid sequences. These derivatives can be used to screen samples, such as blood, to determine if antibodies to hepatitis C virus are present.

Specific binding substances for antibodies and their use for immunoassays or vaccines

PNA monomers with electron donor or acceptor

Monitoring system for the regular intake of a medicament

The subject matter of the invention is a modified phosphoramidite process for the synthesis of nucleotide sequences. By use of a modified nucleoside phosphoramidite it is possible to produce nucleotide sequences which have a modified phosphate residue.

Modified phosphoramidite process for the production of modified nucleic

The invention concerns a binding matrix containing a carrier material with an oxidic surface and a solid phase reactant covalently bound thereto via anchor groups which is capable of binding to at least one free reaction partner, which is characterized in that the solid phase reactant forms a diluted and essentially laterally homogeneous binding layer on the surface of the carrier material and that the anchor groups are silane groups and are linked to the solid phase reactant via a spacer molecule.

Biotinsilane compounds and a binding matrix containing these compounds

Immunogens of formula I are provided for obtaining HbA.sub.1c -specific antibodies ##STR1## M is 1 to 40, T is a carrier protein and A is a 10-20 atoms spacer and is ##STR2## where X is S or --NH--, n is 1 to 4 and B is a succinimide containing organic radical. The antibodies obtained bind glycosylated hemoglobin to determine HbA.sub.1c in body fluids.

Immunogens and the use thereof for obtaining antibodies against

The present invention provides immunogens for obtaining HbA.sub.1c -specific antibodies, which immunogens have the general formula: ##STR1## wherein M is 1 to 40, T is a carrier protein and A is a spacer which has a chain length of 10 to 20 atoms and has the general formula: ##STR2## wherein X is a sulphur atom or au --NH-- group, n is 1 to 4 and B is an organic radical which contains a succinimide group. The present invention also provides a process for obtaining antibodies which specifically bind glycosylated haemoglobin, wherein an immunogen of general formula (I) is injected into an organism capable of antibody formation and the antibodies are then obtained in known manner. These antibodies can be used for determining HbA.sub.1c in body fluids.

The invention concerns new aminoalkylmaleimides of the general formula I ##STR1## in which R.sub.1 and R.sub.2 are the same or different and represent hydrogen or a C.sub.1 -C.sub.4 alkyl group and A represents a straight-chain or branched, saturated or unsaturated alkylene group with 2 to 6 carbon atoms which is interrupted, if desired, by an oxygen or sulphur atom or a carbonyl group, as well as their corresponding acid addition salts. The present invention also concerns amidoalkylmaleimide derivatives formed from compounds of the general formula I and immunological binding partners. In addition, the invention concerns immunological conjugates which can be produced by reaction of the amidoalkylmaleimide derivatives with peptides or proteins. The subject matter of the present invention are also the corresponding processes of production of the compounds according to the present invention as well as the use of these conjugates in diagnostic methods of determination, in particular in immunoassays.

Aminoalkylmaleimides and hapten and antigen derivatives derived

Novel compounds having the general formula

Alkyl-substituted aryl-saccharides, surface-active agents which contain

The present invention provides resorufin derivatives of the general formulae: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5, which can be the same or different, are hydrogen, halogen, carboxyl, carboxamido, lower alkoxycarbonyl, cyano or nitro groups or lower alkyl or lower alkoxy radicals, which can be substituted by carboxyl, carboxamido, lower alkoxycarbonyl, cyano or nitro groups, and wherein R.sup.4 and R.sup.5 can together also represent an anellated aromatic residue, Z is a bridge member, A is the residue of a ligand and n is a whole number of from 1 to 200. The present invention also provides processes for the preparation of these resorufin derivatives, as well as intermediates for the preparation thereof.

Resorufin derivatives

Growing community of inventors

Tutzing, Germany

Hans-Georg Batz